- Home
- XPON vs REVB Comparison
XPON vs REVB Comparison
Compare XPON & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- REVB
- Stock Information
- Founded
- XPON 2016
- REVB 2020
- Country
- XPON United States
- REVB United States
- Employees
- XPON N/A
- REVB N/A
- Industry
- XPON Electronic Components
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- XPON Technology
- REVB Health Care
- Exchange
- XPON Nasdaq
- REVB Nasdaq
- Market Cap
- XPON 1.9M
- REVB 2.0M
- IPO Year
- XPON 2022
- REVB N/A
- Fundamental
- Price
- XPON $1.33
- REVB $4.47
- Analyst Decision
- XPON
- REVB
- Analyst Count
- XPON 0
- REVB 0
- Target Price
- XPON N/A
- REVB N/A
- AVG Volume (30 Days)
- XPON 312.5K
- REVB 159.9K
- Earning Date
- XPON 03-27-2025
- REVB 03-21-2025
- Dividend Yield
- XPON N/A
- REVB N/A
- EPS Growth
- XPON N/A
- REVB N/A
- EPS
- XPON N/A
- REVB N/A
- Revenue
- XPON $4,498,181.00
- REVB N/A
- Revenue This Year
- XPON N/A
- REVB N/A
- Revenue Next Year
- XPON $66.62
- REVB N/A
- P/E Ratio
- XPON N/A
- REVB N/A
- Revenue Growth
- XPON N/A
- REVB N/A
- 52 Week Low
- XPON $1.32
- REVB $3.34
- 52 Week High
- XPON $473.00
- REVB $69.44
- Technical
- Relative Strength Index (RSI)
- XPON 30.42
- REVB 38.37
- Support Level
- XPON $1.32
- REVB $3.34
- Resistance Level
- XPON $1.75
- REVB $4.70
- Average True Range (ATR)
- XPON 0.10
- REVB 0.81
- MACD
- XPON -0.01
- REVB -0.12
- Stochastic Oscillator
- XPON 2.18
- REVB 23.24
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles ("RV's") and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).